SRV: Premium Workspace Provider - Peak Performance, Inevitable Decline
HOLD rating with $8.31 fair value. Exceptional 46.2% EBITDA margins face inevitable compression as 74% ROIC attracts competition. Income-focused opportunity only.
View note
HOLD rating with $8.31 fair value. Exceptional 46.2% EBITDA margins face inevitable compression as 74% ROIC attracts competition. Income-focused opportunity only.
View notePre-revenue gold explorer trading at A$0.047 vs A$0.191 fair value. Dual catalysts: systematic exploration across 1,000km² Eastern Goldfields tenure and US$50m arbitration award. High risk, asymmetric upside.
View noteHOLD rating with $1.78 fair value vs $1.99 current price. Strong 80% annuity model offset by margin compression risks and 53% valuation premium to peers.
View noteSpark New Zealand trading at NZ$2.29 vs fair value NZ$3.07, offering 34% upside through transformation execution and defensive infrastructure advantages in dominant market position.
View noteMedical device manufacturer with 35-40% oral appliance market share. Fair value $0.30 vs current $0.70. EBITDA margins compressing, manufacturing constraints binding.
View noteSoul Patts trades at $38.71 vs fair value $45.81, offering 18.4% upside through portfolio evolution and private market access with 122-year dividend track record.
View noteBUY rating with A$4.76 fair value vs A$2.36 current price. Strong balance sheet, operational excellence, 102% upside potential despite commodity volatility.
View noteSpeculative buy with 124% upside to $9.06 fair value. Binary TRL-6 catalyst Q4 2025. Revolutionary laser enrichment technology targeting 8% Western market share.
View noteHOLD rating on Sky Network Television. Fair value NZ$5.68 vs current NZ$2.58 (120% upside). Dominant 80% NZ pay-TV share, 8.5% yield, but 2030 sports rights renewal risk.
View noteElectrical contractor riding data centre wave faces inevitable margin compression. Fair value $1.55 vs current $2.97. EBITDA margins 9.0%, ROIC 84%, but competition emerging.
View noteSonic Healthcare trades at A$28.30 versus A$32.41 fair value, offering 14.5% upside through LADR integration targeting A$130m synergies with 65% achieved.
View noteSHAPE trades at $4.28 vs fair value $3.30. Strong operations (86% Perfect Delivery, 78.6% ROIC) but execution complexity and cycle timing create unfavourable risk-reward.
View note